Tariff-related Litigation Update – 9/12
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Global & Trade
Learn more about our Global Affairs work.
Tariff-related Litigation Update – 9/5
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/22
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/15
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Scott Whitaker Op-Ed: Medtech is vital to a healthier America
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Tariff-related Litigation Update – 7/25
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.
Tariff-related Litigation Update – 7/18
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.
AdvaMed® Advancements: Q2 2025 Report
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.
U.S. Medtech Manufacturing: Driving Innovation, Jobs, & Global Impact
Explore how U.S. medtech manufacturing drives $250B in output, supports 3M jobs, leads in R&D, and fuels global exports.
Tariff-related Litigation Update – 7/11
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 11, 2025.